In the news.
FDA convenes roundtable on cell and gene therapy.
On June 5th, FDA held a cell and gene therapy roundtable discussing rare disease and cancer therapies and the opportunity to consider product development from the patient and family point of view. Leading experts, including ACGT Scientific Advisory Council members and Research Fellows Dr Crystal Mackall and Dr Carl June, were invited to share with FDA the progress and challenges and, most importantly, the incredible potential in curing diseases through cell and gene therapies.
Read More
FDA convenes roundtable on cell and gene therapy.
On June 5th, FDA held a cell and gene therapy roundtable discussing rare disease and cancer therapies and the opportunity to consider product development from the patient and family point of view. Leading experts, including ACGT Scientific Advisory Council members and Research Fellows Dr Crystal Mackall and Dr Carl June, were invited to share with FDA the progress and challenges and, most importantly, the incredible potential in curing diseases through cell and gene therapies.
Read More
Gene therapy trailblazer Rosenberg honored with Edward Netter Leadership Award
On March 20, Alliance for Cancer Gene Therapy awarded The Edward Netter Leadership Award to Steven A. Rosenberg, MD, PhD, at the ACGT Gala Awards Luncheon.
Read More
Gene therapy trailblazer Rosenberg honored with Edward Netter Leadership Award
On March 20, Alliance for Cancer Gene Therapy awarded The Edward Netter Leadership Award to Steven A. Rosenberg, MD, PhD, at the ACGT Gala Awards Luncheon.
Read More
ACGT-Netter Fund awards grant for neuroblastoma CAR T-cell therapy
ACGT has awarded a collaborative research grant to two scientists at Children’s Hospital of Philadelphia who are developing a cell and gene therapy for childhood cancers.
Read More
ACGT-Netter Fund awards grant for neuroblastoma CAR T-cell therapy
ACGT has awarded a collaborative research grant to two scientists at Children’s Hospital of Philadelphia who are developing a cell and gene therapy for childhood cancers.
Read More
ACGT-Netter Fund awards grant for pediatric brain tumor research
The ACGT-Barbara Netter Fund has awarded a collaboration grant to support the development of T-cell therapy for pediatric brain tumors.
Read More
ACGT-Netter Fund awards grant for pediatric brain tumor research
The ACGT-Barbara Netter Fund has awarded a collaboration grant to support the development of T-cell therapy for pediatric brain tumors.
Read More
FDA approves Aucatzyl CAR T-cell therapy for acute lymphoblastic leukemia (ALL)
The US Food and Drug Administration (FDA) has approved Autolus Therapeutics’ Aucatzyl (obecabtagene autoleucel) to treat acute lymphoblastic leukemia (ALL).
Read More
FDA approves Aucatzyl CAR T-cell therapy for acute lymphoblastic leukemia (ALL)
The US Food and Drug Administration (FDA) has approved Autolus Therapeutics’ Aucatzyl (obecabtagene autoleucel) to treat acute lymphoblastic leukemia (ALL).
Read More
